Rewriting the Code of Life with CRISPR-Cas9

Last week, Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics released their third quarter financial results. All three of the biotech companies are currently developing treatments using CRISPR-Cas9 gene editing technology. They are also all still preclinical, with no commercialized products available yet. Editas Medicine was the obvious leader of the group, with a $0.50 increase in EPS; $337.5 million in cash, cash equivalents, and marketable securities; revenue increases from their partnership with Allergan; and progress on their Investigational New Drug (IND) application for their EDIT-101 treatment. Below is an overview of the Q3 financials for all three biotech companies: E

The Ethics of Coding Living Things

One area of the biotech industry I find particularly interesting is genetic engineering. For the past few months, I've been closely following the race between three similar publicly traded companies, all of which are competing to get the first genome editing treatment to market. Their weapon of choice is a gene editing biotechnology called CRISPR-Cas9. The three companies, which should have updated third quarter financials out this week, are: Editas Medicine (NASDAQ: EDIT) CRISPR Therapeutics (NASDAQ: CRSP) Intellia Therapeutics (NASDAQ: NTLA) In my last post on this topic, I gave an overview of the genome editing landscape and described how it's positioned to be the next generation of genet